Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily

Front Pharmacol. 2024 Jul 9:15:1401599. doi: 10.3389/fphar.2024.1401599. eCollection 2024.

Abstract

With over 450 genes, solute carriers (SLCs) constitute the largest transporter superfamily responsible for the uptake and efflux of nutrients, metabolites, and xenobiotics in human cells. SLCs are associated with a wide variety of human diseases, including cancer, diabetes, and metabolic and neurological disorders. They represent an important therapeutic target class that remains only partly exploited as therapeutics that target SLCs are scarce. Additionally, many small molecules reported in the literature to target SLCs are poorly characterized. Both features may be due to the difficulty of developing SLC transport assays that fulfill the quality criteria for high-throughput screening. Here, we report one of the main limitations hampering assay development within the RESOLUTE consortium: the lack of a resource providing high-quality information on SLC tool compounds. To address this, we provide a systematic annotation of tool compounds targeting SLCs. We first provide an overview on RESOLUTE assays. Next, we present a list of SLC-targeting compounds collected from the literature and public databases; we found that most data sources lacked specificity data. Finally, we report on experimental tests of 19 selected compounds against a panel of 13 SLCs from seven different families. Except for a few inhibitors, which were active on unrelated SLCs, the tested inhibitors demonstrated high selectivity for their reported targets. To make this knowledge easily accessible to the scientific community, we created an interactive dashboard displaying the collected data in the RESOLUTE web portal (https://re-solute.eu). We anticipate that our open-access resources on assays and compounds will support the development of future drug discovery campaigns for SLCs.

Keywords: KNIME; solute carrier; tool compound; transport assay; transport protein.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was performed by the RESOLUTE (https://re-solute.eu/), REsolution (https://re-solute.eu/resolution), and EUbOPEN (https://www.eubopen.org/) consortia. Plasmids are available through Addgene (https://www.addgene.org/depositor-collections/re-solute/). RESOLUTE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777372. This joint undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the EFPIA. REsolution has received funding from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034439. This joint undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the EFPIA. EUbOPEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875510. The joint undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program, the EFPIA, Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning–McGill University, Kungliga Tekniska Hoegskolan, and Diamond Light Source Limited. This article reflects only the authors’ views, and neither the IMI nor the European Union and the EFPIA are responsible for any use that may be made of the information contained therein.